Andrii Monastyrskyi

Andrii Monastyrskyi

Auto-generated profile, based on publicly available information

Andrii Monastyrskyi

Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KMKamira Maharaj
Kamira Maharaj
JPJohn J. Powers
John J. Powers
AAAlex Achille
Alex Achille
MMMelanie Mediavilla-Varela
Melanie Mediavilla-Varela
WGWael Gamal
Wael Gamal
JPJavier Pinilla-Ibarz
Javier Pinilla-Ibarz
The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse events has led to frequent discontinuations, limiting the clinical development of these inhibitors. By contrast, the dual PI3Kδ/casein kinase-1-ε (CK1ε) inhibitor umbralisib (TGR-1202) also shows high rates of response in clinical trials but has an improved safety profile with fewer severe adverse events. Toxicities typical of this class of PI3K inhibitors are largely thought to be immune mediated, but they are poorly characterized. Here, we report the effects of idelalisib, duvelisib, and umbralisib on regulatory T cells (Tregs) on normal human T cells, T cells from CLL patients, and T cells in an Eμ-TCL1 adoptive transfer mouse CLL model. Ex vivo studies revealed differential effects of these PI3K inhibitors; only umbralisib treatment sustained normal and CLL-associated FoxP3+ human Tregs. Further, although all 3 inhibitors exhibit antitumor efficacy in the Eμ-TCL1 CLL model, idelalisib- or duvelisib-treated mice displayed increased immune-mediated toxicities, impaired function, and reduced numbers of Tregs, whereas Treg number and function were preserved in umbralisib-treated CLL-bearing mice. Finally, our studies demonstrate that inhibition of CK1ε can improve CLL Treg number and function. Interestingly, CK1ε inhibition mitigated impairment of CLL Tregs by PI3K inhibitors in combination treatment. These results suggest that the improved safety profile of umbralisib is due to its role as a dual PI3Kδ/CK1ε inhibitor that preserves Treg number and function.

9 December 2020 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
STSolomon Tadesse
Solomon Tadesse
DDDerek R Duckett
Derek R Duckett
AMAndrii Monastyrskyi
Andrii Monastyrskyi
CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, ...

1 February 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AMAndrii Monastyrskyi
Andrii Monastyrskyi
NNNapon Nilchan
Napon Nilchan
VQVictor Quereda
Victor Quereda
YNYoshihiko Noguchi
Yoshihiko Noguchi
CRClaudia Ruiz
Claudia Ruiz
WRWilliam Roush
William Roush

26 November 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MSMaximilian Schmitz
Maximilian Schmitz
IKInes H. Kaltheuner
Ines H. Kaltheuner
KAKanchan Anand
Kanchan Anand
RDRobert Düster
Robert Düster
JMJonas Moecking
Jonas Moecking
MGMatthias Geyer
Matthias Geyer
Inhibition of cyclin-dependent kinases (CDKs) has evolved as an emerging anticancer strategy. In addition to the cell cycle-regulating CDKs, the transcriptional kinases Cdk12 and Cdk13 have become the focus of interest as they mediate a variety of functions, including the transition from transcription initiation to elongation and termination, precursor mRNA splicing, and intronic polyadenylation. Here, we determine the crystal structure of the small molecular inhibitor SR-4835 bound to the Cdk12/cyclin K complex at 2.68 Å resolution. The compound's benzimidazole moiety is embedded in a unique hydrogen bond network mediated by the kinase hinge region with flanking hydroxy groups of the Y815 and D819 side chains. Whereas the SR-4835 head group targets the adenine-binding pocket, the kinase's glycine-rich loop is shifted down toward the activation loop. Additionally, the αC-helix adopts an inward conformation, and the phosphorylated T-loop threonine interacts with all three canonical arginines, a hallmark of CDK activation that is altered in Cdk12 and Cdk13. Dose-response inhibition measurements with recombinant CMGC kinases show that SR-4835 is highly specific for Cdk12 and Cdk13 following a 10-fold lower potency for Cdk10. Whereas other CDK-targeting compounds exhibit tighter binding affinities and higher potencies for kinase inhibition, SR-4835 can be considered a selective transcription elongation antagonist. Our results provide the basis for a rational improvement of SR-4835 toward Cdk12 inhibition and a gain in selectivity over other transcription regulating CDKs.

13 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
KBKaren L. Burger
Karen L. Burger
MFMario R. Fernandez
Mario R. Fernandez
MMMark B. Meads
Mark B. Meads
PSPraneeth Reddy Sudalagunta
Praneeth Reddy Sudalagunta
POPaula S. Oliveira
Paula S. Oliveira
KSKenneth H. Shain
Kenneth H. Shain
Multiple myeloma remains an incurable malignancy due to acquisition of intrinsic programs that drive therapy resistance. Here we report that casein kinase-1δ (CK1δ) and CK1ε are therapeutic targets in multiple myeloma that are necessary to sustain mitochondrial metabolism. Specifically, the dual CK1δ/CK1ε inhibitor SR-3029 had potent in vivo and ex vivo anti–multiple myeloma activity, including against primary multiple myeloma patient specimens. RNA sequencing (RNA-seq) and metabolic analyses revealed inhibiting CK1δ/CK1ε disables multiple myeloma metabolism by suppressing genes involved in oxidative phosphorylation (OxPhos), reducing citric acid cycle intermediates, and suppressing complexes I and IV of the electron transport chain. Finally, sensitivity of multiple myeloma patient specimens to SR-3029 correlated with elevated expression of mitochondrial genes, and RNA-seq from 687 multiple myeloma patient samples revealed that increased CSNK1D, CSNK1E, and OxPhos genes correlate with disease progression and inferior outcomes. Thus, increases in mitochondrial metabolism are a hallmark of multiple myeloma progression that can be disabled by targeting CK1δ/CK1ε. Significance: CK1δ and CK1ε are attractive therapeutic targets in multiple myeloma whose expression increases with disease progression and connote poor outcomes, and that are necessary to sustain expression of genes directing OxPhos.

11 October 2024 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
PGPompom Ghosh
Pompom Ghosh
MSMaximilian Schmitz
Maximilian Schmitz
TPThiyagamurthy Pandurangan
Thiyagamurthy Pandurangan
SZSolomon Tadesse Zeleke
Solomon Tadesse Zeleke
SCSean Chin Chan
Sean Chin Chan
AMAndrii Monastyrskyi
Andrii Monastyrskyi
De novo design of molecular glues transforming CDK12 inhibitors, including dinaciclib, into cyclin K degraders.